OKYO Pharma's CEO Gary Jacob says its drug candidate OK-101 which was developed to treat dry eye diseases through its anti-inflammatory mode of action has also shown potent ocular pain reducing properties. He says there's now the potential to treat both pain and inflammation, the most common symptoms of dry eye, with a single drug.
OKYO Pharma highlights ocular pain-reducing potential of drug candidate OK-101
